Figure 5.
Everolimus (red line) compared to placebo (black line) on patients who have progressed on at least one vascular endothelial growth factor tyrosine kinase inhibitor – RECORD-1 Trial [Motzer et al. 2008b]. With permission, The Lancet.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.